Bloodstream infections with rapidly growing nontuberculous mycobacteria

Comba, Isin Yagmur; Tabaja, Hussam; Almeida, Natalia E. Castillo; Fida, Madiha; Saleh, Omar Abu

doi:10.1016/j.jctube.2021.100288

Cited by 8 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar relationships were observed by Pang et al: sensitivity to tigecycline was found for 96% (53/55) of strains from the M. abscessus complex, 91% (10/11) of M. fortuitum strains, and 100% (3/3) of M. chelonae strains [ 52 ]. Similarly, in a study by Comba et al, the MIC value was <0.25 µg/mL for 45.7% of the strains (16/35), and from 0.25 µg/mL to 0.5 µg for 54.3% of the strains (19/35) [ 53 ]. According to worldwide reports, tigecycline is used in the treatment of the most severe infections with RGM mycobacteria, but to date there are no CLSI guidelines for the interpretation of MIC values in the AST.…”

Section: Discussionmentioning

confidence: 86%

New RAPMYCOI SensititreTM Antimicrobial Susceptibility Test for Atypical Rapidly Growing Mycobacteria (RGM)

Borek¹,

Zabost²,

Głogowska³

et al. 2022

Diagnostics

View full text Add to dashboard Cite

Rapidly growing mycobacteria (RGM) cause an increasing international concern, mainly due to their natural resistance to many antibiotics. The aim of this study was to conduct species identification and determine the antimicrobial susceptibility profiles of RGM isolated in Poland. Antimicrobial susceptibility was tested using broth microdilution and the RAPMYCOI panel. A total of 60 strains were analysed, including the following species: M. fortuitum complex (30), M. abscessus subsp. abscessus (16), M. abscessus subsp. massiliense (7), M. chelonae (5), and M. mucogenicum (2). For 12 M. abscessus subsp. abscessus strains, the presence of the erm 41T28 genotype associated with inducible macrolide resistance and a functional erm gene was confirmed. A MUT2 mutation in the rrl gene (constitutive resistance) was identified for two strains from the subtype M. abscessus subsp. massiliense. Among the 15 tested antibiotics, amikacin and linezolid had the strongest antimycobacterial activity. Most of the tested strains were resistant to doxycycline and trimethoprim/sulfamethoxazole. Tigecycline MICs were low for all tested strains. Findings from our study highlight the importance of correct identification of clinical isolates and antimicrobial susceptibility testing.

show abstract

Section: Discussionmentioning

confidence: 86%

New RAPMYCOI SensititreTM Antimicrobial Susceptibility Test for Atypical Rapidly Growing Mycobacteria (RGM)

Borek¹,

Zabost²,

Głogowska³

et al. 2022

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Monotherapy (clarithromycin) has shown promising efficacy in uncomplicated non-pulmonary disease, probably because its hand and foot lesions may represent a self-limited characteristic (Lee et al, 2015). However, invasive or disseminated M. abscessus and M. bolletii infections are complicated to treat; a combination of medication and a more comprehensive treatment course are necessary (Comba et al, 2021). Surgical resection of the infected tissues following chemotherapy to lessen the extensive progress might be a possible curative treatment for complex cases.…”

Section: Mycobacterium Abscessus Groupmentioning

confidence: 99%

The Evolution in Pharmacology of Infectious Diseases: 2022

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…Monotherapy (clarithromycin) has shown promising efficacy in uncomplicated non-pulmonary disease, probably because its hand and foot lesions may represent a self-limited characteristic ( Lee et al, 2015 ). However, invasive or disseminated M. abscessus and M. bolletii infections are complicated to treat; a combination of medication and a more comprehensive treatment course are necessary ( Comba et al, 2021 ). Surgical resection of the infected tissues following chemotherapy to lessen the extensive progress might be a possible curative treatment for complex cases.…”

Section: Main Textmentioning

confidence: 99%

Treatment of non-tuberculosis mycobacteria skin infections

Wang,

Jia,

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Non-tuberculosis mycobacteria (NTM) skin infections have become increasingly prevalent in recent years, presenting a unique challenge in clinical management. This review explored the complexities of NTM infections localized to the superficial tissues and provided valuable insights into the optimal therapeutic strategies. The antibiotic selection should base on NTM species and their susceptibility profiles. It is recommended to adopt a comprehensive approach that considers the unique characteristics of superficial tissues to improve treatment effectiveness and reduce the incidence of adverse reactions, infection recurrence, and treatment failure. Infection control measures, patient education, and close monitoring should complement the treatment strategies to achieve favorable outcomes in managing NTM skin infections. Further efforts are warranted to elucidate factors and mechanisms contributing to treatment resistance and relapse. Future research should focus on exploring novel treatment options, innovative drug development/delivery platforms, and precise methodologies for determining therapeutic duration. Longitudinal studies are also needed to assess the long-term safety profiles of the integrated approaches.

show abstract

Bloodstream infections with rapidly growing nontuberculous mycobacteria

Cited by 8 publications

References 32 publications

New RAPMYCOI SensititreTM Antimicrobial Susceptibility Test for Atypical Rapidly Growing Mycobacteria (RGM)

New RAPMYCOI SensititreTM Antimicrobial Susceptibility Test for Atypical Rapidly Growing Mycobacteria (RGM)

The Evolution in Pharmacology of Infectious Diseases: 2022

Treatment of non-tuberculosis mycobacteria skin infections

Contact Info

Product

Resources

About